Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, non-controlled, dose-escalation study in patients with relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma

Trial Profile

A multicenter, open-label, non-controlled, dose-escalation study in patients with relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Selinexor (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 01 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 23 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top